2 assets in Congenital Isolated Hyperinsulinism

Therapeutic assets addressing Congenital Isolated Hyperinsulinism, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
FDOPA Congenital Isolated Hyperinsulinism	University of Alberta	P3	BB (66)
Furosemide Congenital Isolated Hyperinsulinism	University of Alberta	P3	B (60)